This was based on the result of the KRYSTAL-1 trial, a single arm, phase I/II trial for pretreated advanced NSCLC with KRAS G12C mutation, which demonstrated an ORR of 42.9% with mPFS and mOS of 6.5 and 12.6 months, respectively (12). This evidence concerns the gene KRAS and non-small cell lung carcinoma.